Cinrebafusp alfa clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses cinrebafusp alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PRS-343
- 1
Studies by the year they started
3 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 1 |
Who runs them
Industry 3 · Other 0
Pieris Pharmaceuticals, Inc. (3)
Studies
Open first, then newest update. How each study uses cinrebafusp alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- PRS-343 in Combination With Atezolizumab in HER2-Positive Solid TumorsCompletedPhase 1Pieris Pharmaceuticals, Inc.NCT03650348Written as PRS-343 in Combination with Atezolizumab
- PRS-343 in HER2-Positive Solid TumorsCompletedPhase 1Pieris Pharmaceuticals, Inc.NCT03330561Written as PRS-343
- Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ AndenocarinomaActive, not recruitingPhase 2Pieris Pharmaceuticals, Inc.NCT05190445Written as Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel
Codes
What other systems call cinrebafusp alfa · ClinicalTrials.gg INT014382
- UNII (FDA) 21Z359Z1CVCINREBAFUSP ALFAOne source FDA
- NCI Thesaurus C142890Cinrebafusp AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 21Z359Z1CV | CINREBAFUSP ALFA | One source FDA |
| NCI Thesaurus | C142890 | Cinrebafusp Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.